Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Paul G. Richardson, Susanna J. Jacobus, Edie A. Weller, Hani Hassoun, Sagar Lonial, Noopur S. Raje, Eva Medvedova, Philip L. McCarthy, Edward N. Libby, Peter M. Voorhees, Robert Z. Orlowski, Larry D. Anderson, Jeffrey A. Zonder, Carter P. Milner, Cristina Gasparetto, Mounzer E. Agha, Abdullah M. Khan, David D. Hurd, Krisstina Gowin, Rammurti T. KambleSundar Jagannath, Nitya Nathwani, Melissa Alsina, R. Frank Cornell, Hamza Hashmi, Erica L. Campagnaro, Astrid C. Andreescu, Teresa Gentile, Michaela Liedtke, Kelly N. Godby, Adam D. Cohen, Thomas H. Openshaw, Marcelo C. Pasquini, Sergio A. Giralt, Jonathan L. Kaufman, Andrew J. Yee, Emma Scott, Pallawi Torka, Amy Foley, Mariateresa Fulciniti, Kyle Hebert, Mehmet K. Samur, Kelly Masone, Michelle E. Maglio, Andrea A. Zeytoonjian, Omar Nadeem, Robert L. Schlossman, Jacob P. Laubach, Claudia Paba-Prada, Irene M. Ghobrial, Aurore Perrot, Philippe Moreau, Hervé Avet-Loiseau, Michel Attal, Kenneth C. Anderson, Nikhil C. Munshi

Research output: Contribution to journalArticlepeer-review

196 Scopus citations


BACKGROUND In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until disease progression, is unknown. METHODS In this phase 3 trial, adults (18 to 65 years of age) with symptomatic myeloma received one cycle of RVD. We randomly assigned these patients, in a 1:1 ratio, to receive two additional RVD cycles plus stem-cell mobilization, followed by either five additional RVD cycles (the RVD-alone group) or high-dose melphalan plus ASCT followed by two additional RVD cycles (the transplantation group). Both groups received lenalidomide until disease progression, unacceptable side effects, or both. The primary end point was progression-free survival. RESULTS Among 357 patients in the RVD-alone group and 365 in the transplantation group, at a median follow-up of 76.0 months, 328 events of disease progression or death occurred; the risk was 53% higher in the RVD-alone group than in the transplantation group (hazard ratio, 1.53; 95% confidence interval [CI], 1.23 to 1.91; P<0.001); median progression-free survival was 46.2 months and 67.5 months. The percentage of patients with a partial response or better was 95.0% in the RVD-alone group and 97.5% in the transplantation group (P=0.55); 42.0% and 46.8%, respectively, had a complete response or better (P=0.99). Treatment-related adverse events of grade 3 or higher occurred in 78.2% and 94.2%, respectively; 5-year survival was 79.2% and 80.7% (hazard ratio for death, 1.10; 95% CI, 0.73 to 1.65). CONCLUSIONS Among adults with multiple myeloma, RVD plus ASCT was associated with longer progression-free survival than RVD alone. No overall survival benefit was observed.

Original languageEnglish
Pages (from-to)132-147
Number of pages16
JournalNew England Journal of Medicine
Issue number2
StatePublished - 14 Jul 2022


Dive into the research topics of 'Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma'. Together they form a unique fingerprint.

Cite this